<DOC>
	<DOCNO>NCT00150085</DOCNO>
	<brief_summary>New onset diabetes mellitus ( NODM ) post- transplantation decrease patient graft survival . Some immunosuppressive agent associate high incidence NODM . This study evaluate safety efficacy convert patient NODM tacrolimus cyclosporine micro-emulsion primary immunosuppressant kidney liver recipient .</brief_summary>
	<brief_title>Safety Efficacy Converting Maintenance Kidney Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus Cyclosporine Micro-emulsion</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Recipients first second cadaveric live donor kidney transplantation first cadaveric living donor liver transplantation Receiving tacrolimus primary immunosuppressant Currently diabetic agent meet American Diabetes Association definition diabetes mellitus History treat diabetes mellitus prior transplantation Less 2 week posttransplantation kidney le 8 week liver Greater 36 month posttransplantation Onset diabetes great 12 month prior time study entry Has unacceptable unstable graft function Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>diabetes , glucose , tacrolimus , cyclosporine micro-emulsion , liver , kidney , renal</keyword>
</DOC>